<p>Stevens Capital Management LP 在第二季度购买了强生公司（NYSE:JNJ - 免费报告）的新股份，根据该公司最近向证券交易委员会提交的 13F 表格。该机构投资者购买了 12,443 股公司的股票，价值约为 1,901,000 美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>为什么 GRAIL 股票可能是生物科技的下一个重大突破</li>
</ul>
<p>其他对冲基金和机构投资者最近也调整了对该公司的持股。GFG Capital LLC 在第二季度购买了价值约 35,000 美元的强生新股份。Stone House Investment Management LLC 在第一季度购买了价值约 47,000 美元的强生新股份。1248 Management LLC 在第一季度购买了价值 48,000 美元的强生新股份。Harvest Fund Management Co. Ltd 在第一季度购买了价值约 52,000 美元的强生新股份。最后，Pandora Wealth Inc. 在第一季度购买了价值 65,000 美元的强生新股份。目前 69.55% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>内部买卖</h2>
<p>在相关消息中，执行副总裁 Jennifer L. Taubert 于 9 月 4 日星期四出售了 56,471 股公司的股票。股票以平均价格 177.81 美元出售，总价值为 10,041,108.51 美元。出售完成后，该执行副总裁持有 178,013 股公司的股票，价值 31,652,491.53 美元。这代表其持股减少了 24.08%。该交易已在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站获取。目前公司内部人士持有 0.16% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>3 只适合不安市场的聪明防御性股票</li>
</ul>
<p>多家券商对 JNJ 发表了看法。Sanford C. Bernstein 将强生的目标价格从 172.00 美元上调至 193.00 美元，并在 10 月 6 日的研究报告中给予该公司 “市场表现” 评级。Johnson Rice 对强生的股票设定了 190.00 美元的目标价格，并在 10 月 22 日的报告中给予该股票 “持有” 评级。汇丰银行将强生股票的目标价格从 210.00 美元上调至 215.00 美元，并在 10 月 16 日的研究报告中给予该公司 “买入” 评级。瑞银集团将强生的目标价格从 190.00 美元上调至 214.00 美元，并在 10 月 14 日的研究报告中给予该公司 “买入” 评级。最后，Argus 在 10 月 15 日的报告中对强生股票设定了 210.00 美元的目标价格。四位股票研究分析师给予该股票 “强烈买入” 评级，十三位给予 “买入” 评级，九位给予 “持有” 评级。根据 MarketBeat，强生的共识评级为 “适度买入”，平均目标价格为 201.05 美元。</p>
<p><strong>查看我们对 JNJ 的最新分析</strong></p>
<h2>强生股票表现</h2>
<ul>
<li>持有评级，高回报？3 只可能超出预期的股票</li>
</ul>
<p>强生股票在周五开盘价为 203.88 美元。该公司的速动比率为 0.80，流动比率为 1.07，债务与股本比率为 0.50。该公司的市值为 4912.1 亿美元，市盈率为 19.68，市盈增长比率为 2.19，贝塔值为 0.38。该公司的 50 日简单移动平均为 188.25 美元，200 日简单移动平均为 171.55 美元。强生的 52 周低点为 140.68 美元，52 周高点为 206.94 美元。</p>
<p>强生（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日星期三发布了季度收益数据。该公司报告每股收益为 2.26 美元。该季度的营业收入为 240.2 亿美元。强生的股本回报率为 32.73%，净利润率为 27.26%。股票分析师预测强生在当前年度的每股收益将达到 10.58 美元。</p>
<h2>强生股息公告</h2>
<p>该公司最近还宣布了一项季度股息，将于 12 月 9 日星期二支付。11 月 25 日星期二的股东将获得每股 1.30 美元的股息。除息日期为 11 月 25 日星期二。这代表年化股息为 5.20 美元，股息收益率为 2.6%。强生的派息比率为 50.19%。</p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗保健领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过强生</li>
<li>便士股票适合你的投资组合吗？</li>
<li>收入投资者注意：这只 REIT 正在打折</li>
<li>最大股票亏损者 - 今天最大百分比下跌者</li>
<li>Rocket Lab 刚经历了第一次真正的崩溃——反弹可能更大</li>
<li>标普 500 股票告诉投资者市场的什么？</li>
<li>MarketBeat 周回顾 – 11/17 - 11/21</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Stevens Capital Management LP 在第二季度收购了价值 1,901,000 美元的强生（NYSE:JNJ）12,443 股，具体信息见其最新的 SEC 文件。其他机构投资者也调整了他们的持股。强生的股票在周五开盘价为 203.88 美元，市值为 4,912.1 亿美元。分析师对该股票给予了 “适度买入” 的共识评级，平均目标价格为 201.05 美元</p>

<p>Stevens Capital Management LP bought a new stake in Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor bought 12,443 shares of the company's stock, valued at approximately $1,901,000.</p>
<div class="lb-trans"><p>Stevens Capital Management LP 在第二季度购买了强生公司（NYSE:JNJ - 免费报告）的新股份，根据该公司最近向证券交易委员会提交的 13F 表格。该机构投资者购买了 12,443 股公司的股票，价值约为 1,901,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能是生物科技的下一个重大突破</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also recently modified their holdings of the company. GFG Capital LLC bought a new position in Johnson &amp; Johnson in the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson &amp; Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new stake in shares of Johnson &amp; Johnson in the first quarter valued at $48,000. Harvest Fund Management Co. Ltd bought a new stake in Johnson &amp; Johnson in the first quarter worth about $52,000. Finally, Pandora Wealth Inc. purchased a new position in Johnson &amp; Johnson during the 1st quarter valued at $65,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也调整了对该公司的持股。GFG Capital LLC 在第二季度购买了价值约 35,000 美元的强生新股份。Stone House Investment Management LLC 在第一季度购买了价值约 47,000 美元的强生新股份。1248 Management LLC 在第一季度购买了价值 48,000 美元的强生新股份。Harvest Fund Management Co. Ltd 在第一季度购买了价值约 52,000 美元的强生新股份。最后，Pandora Wealth Inc. 在第一季度购买了价值 65,000 美元的强生新股份。目前 69.55% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Jennifer L. Taubert 于 9 月 4 日星期四出售了 56,471 股公司的股票。股票以平均价格 177.81 美元出售，总价值为 10,041,108.51 美元。出售完成后，该执行副总裁持有 178,013 股公司的股票，价值 31,652,491.53 美元。这代表其持股减少了 24.08%。该交易已在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站获取。目前公司内部人士持有 0.16% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>3 Smart Defensive Stocks for an Uneasy Market</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只适合不安市场的聪明防御性股票</li>
</ul>
</div><p>A number of brokerages have weighed in on JNJ. Sanford C. Bernstein lifted their target price on Johnson &amp; Johnson from $172.00 to $193.00 and gave the company a &#34;market perform&#34; rating in a research report on Monday, October 6th. Johnson Rice set a $190.00 price target on shares of Johnson &amp; Johnson and gave the stock a &#34;hold&#34; rating in a report on Wednesday, October 22nd. HSBC increased their price objective on shares of Johnson &amp; Johnson from $210.00 to $215.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 16th. UBS Group boosted their price target on Johnson &amp; Johnson from $190.00 to $214.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, October 14th. Finally, Argus set a $210.00 target price on shares of Johnson &amp; Johnson in a report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Johnson &amp; Johnson has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $201.05.</p>
<div class="lb-trans"><p>多家券商对 JNJ 发表了看法。Sanford C. Bernstein 将强生的目标价格从 172.00 美元上调至 193.00 美元，并在 10 月 6 日的研究报告中给予该公司 “市场表现” 评级。Johnson Rice 对强生的股票设定了 190.00 美元的目标价格，并在 10 月 22 日的报告中给予该股票 “持有” 评级。汇丰银行将强生股票的目标价格从 210.00 美元上调至 215.00 美元，并在 10 月 16 日的研究报告中给予该公司 “买入” 评级。瑞银集团将强生的目标价格从 190.00 美元上调至 214.00 美元，并在 10 月 14 日的研究报告中给予该公司 “买入” 评级。最后，Argus 在 10 月 15 日的报告中对强生股票设定了 210.00 美元的目标价格。四位股票研究分析师给予该股票 “强烈买入” 评级，十三位给予 “买入” 评级，九位给予 “持有” 评级。根据 MarketBeat，强生的共识评级为 “适度买入”，平均目标价格为 201.05 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我们对 JNJ 的最新分析</strong></p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>强生股票表现</h2>
</div><ul>
<li>Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations</li>
</ul>
<div class="lb-trans"><ul>
<li>持有评级，高回报？3 只可能超出预期的股票</li>
</ul>
</div><p>Shares of Johnson &amp; Johnson stock opened at $203.88 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market cap of $491.21 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The business's fifty day simple moving average is $188.25 and its 200-day simple moving average is $171.55. Johnson &amp; Johnson has a 52 week low of $140.68 and a 52 week high of $206.94.</p>
<div class="lb-trans"><p>强生股票在周五开盘价为 203.88 美元。该公司的速动比率为 0.80，流动比率为 1.07，债务与股本比率为 0.50。该公司的市值为 4912.1 亿美元，市盈率为 19.68，市盈增长比率为 2.19，贝塔值为 0.38。该公司的 50 日简单移动平均为 188.25 美元，200 日简单移动平均为 171.55 美元。强生的 52 周低点为 140.68 美元，52 周高点为 206.94 美元。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%. Equities analysts forecast that Johnson &amp; Johnson will post 10.58 earnings per share for the current year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日星期三发布了季度收益数据。该公司报告每股收益为 2.26 美元。该季度的营业收入为 240.2 亿美元。强生的股本回报率为 32.73%，净利润率为 27.26%。股票分析师预测强生在当前年度的每股收益将达到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>强生股息公告</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.6%. Johnson &amp; Johnson's payout ratio is 50.19%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 12 月 9 日星期二支付。11 月 25 日星期二的股东将获得每股 1.30 美元的股息。除息日期为 11 月 25 日星期二。这代表年化股息为 5.20 美元，股息收益率为 2.6%。强生的派息比率为 50.19%。</p>
</div><h2>Johnson &amp; Johnson Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗保健领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Attention Income Investors: This REIT Is on Sale</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>Rocket Lab Just Had Its First Real Crash—The Rebound Could Be Bigger</li>
<li>What Do S&amp;P 500 Stocks Tell Investors About the Market?</li>
<li>MarketBeat Week in Review – 11/17 - 11/21</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过强生</li>
<li>便士股票适合你的投资组合吗？</li>
<li>收入投资者注意：这只 REIT 正在打折</li>
<li>最大股票亏损者 - 今天最大百分比下跌者</li>
<li>Rocket Lab 刚经历了第一次真正的崩溃——反弹可能更大</li>
<li>标普 500 股票告诉投资者市场的什么？</li>
<li>MarketBeat 周回顾 – 11/17 - 11/21</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Stevens Capital Management LP 在强生公司 $JNJ 中建立了头寸